Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (231-240 of 418) with videos related to

Pageof 42
Sort By:
Cancer|July 22, 2014
Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks settingAntoine Italiano, Axel Le Cesne, Jean Mendiboure, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsRastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Cancer|June 20, 2014
Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-upMaud Toulmonde, Axel Le Cesne, Jean Mendiboure, et al.
Cancer|March 16, 2017
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysisVincent Berry, Laurent Basson, Emilie Bogart, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Oncoimmunology|January 9, 2018
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategiesMarie Kostine, Inge H Briaire-de Bruijn, Arjen H G Cleven, et al.
The Lancet. Oncology|March 14, 2016
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational studyAntoine Italiano, Ilaria Di Mauro, Jocelyn Rapp, et al.
Nature Cancer|April 9, 2025
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysisSophie Cousin, Jean-Philippe Guégan, Lola Jade Palmieri, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
Pageof 42

Showing results (231-240 of 418) with videos related to

Sort By:
Pageof 42
Cancer|July 22, 2014
Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks settingAntoine Italiano, Axel Le Cesne, Jean Mendiboure, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid TumorsRastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Cancer|June 20, 2014
Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-upMaud Toulmonde, Axel Le Cesne, Jean Mendiboure, et al.
Cancer|March 16, 2017
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysisVincent Berry, Laurent Basson, Emilie Bogart, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Oncoimmunology|January 9, 2018
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategiesMarie Kostine, Inge H Briaire-de Bruijn, Arjen H G Cleven, et al.
The Lancet. Oncology|March 14, 2016
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational studyAntoine Italiano, Ilaria Di Mauro, Jocelyn Rapp, et al.
Nature Cancer|April 9, 2025
Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysisSophie Cousin, Jean-Philippe Guégan, Lola Jade Palmieri, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
International Journal of Cancer|February 1, 2018
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Lars H Lindner, Saskia Litière, Stefan Sleijfer, et al.
Pageof 42